Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1.
PMID: 34871089
2022
Antimicrobial agents and chemotherapy
Method: Patients with previously documented HIV-2 infection, with active AIDS, and with documented genotypic evidence of >=1 NNRTI resistance-associated mutation (RAM) from a predefined list of the following NNRTI RAMs at screening were excluded: A98G, L100I, K101E, K101P, K101Q, K103H, K103N, K103S, K103T, V106A, V106M, V108I, E138A, E138G,
HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
PMID: 34762770
2021
Journal of the International AIDS Society
Abstract: Overall, 18/168 (11%) had NNRTI mutations including K101E, K103N/S, V106M, V108I, E138A/G, V179D/I/T
Result: V179I or V179T alone was susceptible to DPV (1.0 and 1.4-FC), while E138A alone had 4.7-FC with respect to wild-type HIV-1.
Table: V179I/T
Table: V179T
Figure: These recombinants are depicted as follows: DPV-1 is HIV-1E138A/V179IT, DPV-2 is HIV-1V108IV/E138A, DPV-3 is HIV-1E138A/V179D.
High HIV-1 Virological Failure and Drug Resistance among Adult Patients Receiving First-Line ART for At least 12 Months at a Decentralized Urban HIV Clinic Setting in Senegal before the Test-and-Treat.
Result: CS detected an additional 7 individuals with mutations conferring drug resistance to etravirine only (E38AV; V90IV; E138A; V179T; A98AG, V179T; V179DV; and A98G), who were wild-type at OLA codons.
Prevalence of HIV-1 Drug-Resistance Genotypes Among Unique Recombinant Forms from Yunnan Province, China in 2016-2017.
PMID: 31914782
2020
AIDS research and human retroviruses
Abstract: Mutations such as M184V/I (35.4%) in NRTIs and K103N/R/S/T (25.4%), V179D/E/T/Y (18.9%), G190A/E/R/S (13.8%), and Y181C (9.2%) in NNRTIs were common among the HIV-1 URF strains relative to other mutations.
HIV-1 subtypes and drug resistance mutations among female sex workers varied in different cities and regions of the Democratic Republic of Congo.
Result: The K103N mutation was the most common, followed by E138A/G, G190A and A98G, and then V179D/E/T and Y181C (Table 2).
Table: V179T
Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.
Abstract: The mutation rate at 14 sites increased significantly at TF time point compared to baseline, with the most common DRMs comprising G190S/C, K65R, K101E/N/Q, M184 V/I, and V179D/I/A/T/E, ranging from 66.7 to 45.2%.
Result: Nine known DRMs ( Result: The NNRTI-associated DRMs detected at TF time point included G190S/C (66.7%), K101E/N/Q (52.4%), V179D/I/A/T/E (45.2%), Y181C (42.9%), K103R/N/S (42.9%), and V106 M (23.8%) (Table 1).
HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.
Result: NNRTI-associated DRMs with extensively drug resistance such as G190A/E/K/Q/S/V, V179I/D/E/T, Y181C/V, and K101E/H/P reside in CRF55_01B and subtype B, C.
Discussion: NRTI-associated DRMs M184I/V and K65R and NNRTI-associated DRMs with extensively drug resistance K101E/H/P, V179I/D/E/T, Y181C/V, and G190A/E/K/Q/S/V were detected in CRF55_01B.
HIV-1 Genetic Diversity and High Prevalence of Pretreatment Drug Resistance in Tianjin, China.
PMID: 32539490
2020
AIDS research and human retroviruses
Abstract: The most frequent mutation pattern against NNRTIs was V179D/E/T (6.9%, 21/305), with M184V (1.0%, 3/305) and K65R (1.0%, 3/305) against nucleoside RT inhibitors (NRTIs).
HIV mutation literature information.
PMID: 
2022
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT